B cell activating factor is central to bleomycin- and IL-17-mediated experimental pulmonary fibrosis

Journal of Autoimmunity

Volumn 56, Issue , 2015, Pages 1-11

  François, Antoine ^a   Gombault, Aurélie ^b   Villeret, Bérengère ^b   Alsaleh, Ghada ^a   Fanny, Manoussa ^b   Gasse, Paméla ^b   Adam, Sylvain Marchand ^c   Crestani, Bruno ^d   Sibilia, Jean ^a   Schneider, Pascal ^e   Bahram, Seiamak ^a   Quesniaux, Valérie ^b   Ryffel, Bernhard ^b   Wachsmann, Dominique ^a   Gottenberg, Jacques Eric ^a   Couillin, Isabelle ^b  

^a UNIVERSITÉ DE STRASBOURG   (France)

^b UNIVERSITÉ D'ORLÉANS   (France)

^c UNIVERSITÉ DE TOURS   (France)

^d BICHAT HOSPITAL   (France)

^e UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

Autoimmunity; BAFF; IL 17; IL 1 ; Pulmonary fibrosis; Systemic sclerosis

Indexed keywords

B CELL ACTIVATING FACTOR; BLEOMYCIN; COLONY STIMULATING FACTOR 1; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 23; INTERLEUKIN 6; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRANSFORMING GROWTH FACTOR BETA1; ANTINEOPLASTIC ANTIBIOTIC; MONOCLONAL ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD3+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; EX VIVO STUDY; EXPERIMENTAL PULMONARY FIBROSIS; HUMAN; LUNG LAVAGE; MOUSE; MURINE MODEL; NEUTROPHIL; NONHUMAN; PROTEIN EXPRESSION; ANIMAL; ANTAGONISTS AND INHIBITORS; DEFICIENCY; DISEASE MODEL; DRUG EFFECTS; FIBROSIS; GENE EXPRESSION; GENETICS; IDIOPATHIC PULMONARY FIBROSIS; IMMUNOLOGY; KNOCKOUT MOUSE; LUNG; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION; T LYMPHOCYTE;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTIBODIES, MONOCLONAL; B-CELL ACTIVATING FACTOR; BLEOMYCIN; BRONCHOALVEOLAR LAVAGE FLUID; DISEASE MODELS, ANIMAL; FIBROSIS; GENE EXPRESSION; IDIOPATHIC PULMONARY FIBROSIS; INTERLEUKIN-17; INTERLEUKIN-1BETA; LUNG; MICE; MICE, KNOCKOUT; NEUTROPHILS; SIGNAL TRANSDUCTION; T-LYMPHOCYTES;

EID: 84920121547     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2014.08.003     Document Type: Article

References (53)

1. Zeki A.A., Schivo M., Chan A.L., Hardin K.A., Kenyon N.J., Albertson T.E., et al. Geoepidemiology of COPD and idiopathic pulmonary fibrosis. JAutoimmun 2010, 34:J327-J338.
2. Hudson M., Fritzler M.J. Diagnostic criteria of systemic sclerosis. JAutoimmun 2014, 48-49:38-41.
3. Barrera M.J., Bahamondes V., Sepúlveda D., Quest A.F.G., Castro I., Cortés J., et al. Sjögren's syndrome and the epithelial target: a comprehensive review. JAutoimmun 2013, 42:7-18.
4. Wynn T.A. Integrating mechanisms of pulmonary fibrosis. JExp Med 2011, 208:1339-1350.
5. Wolters P.J., Collard H.R., Jones K.D. Pathogenesis of idiopathic pulmonary fibrosis. Annu Rev Pathol 2014, 9:157-179.
6. King T.E., Pardo A., Selman M. Idiopathic pulmonary fibrosis. Lancet 2011, 378:1949-1961.
7. Wilson M.S., Wynn T.A. Pulmonary fibrosis: pathogenesis, etiology and regulation. Mucosal Immunol 2009, 2:103-121.
8. Blackwell T.S., Tager A.M., Borok Z., Moore B.B., Schwartz D.A., Anstrom K.J., et al. Future directions in idiopathic pulmonary fibrosis research. An NHLBI workshop report. Am J Respir Crit Care Med 2014, 189:214-222.
9. Crystal R.G., Bitterman P.B., Mossman B., Schwarz M.I., Sheppard D., Almasy L., et al. Future research directions in idiopathic pulmonary fibrosis: summary of a National Heart, Lung, and Blood Institute working group. Am J Respir Crit Care Med 2002, 166:236-246.
10. Bhattacharyya S., Wei J., Tourtellotte W.G., Hinchcliff M., Gottardi C.G., Varga J. Fibrosis in systemic sclerosis: common and unique pathobiology. Fibrogenes Tissue Repair 2012, 5:S18.
11. Luo Y., Wang Y., Wang Q., Xiao R., Lu Q. Systemic sclerosis: genetics and epigenetics. JAutoimmun 2013, 41:161-167.
12. Lahiri A., Pochard P., Le Pottier L., Tobón G.J., Bendaoud B., Youinou P., et al. The complexity of the BAFF TNF-family members: implications for autoimmunity. JAutoimmun 2012, 39:189-198.
13. Nezos A., Papageorgiou A., Fragoulis G., Ioakeimidis D., Koutsilieris M., Tzioufas A.G., et al. B-cell activating factor genetic variants in lymphomagenesis associated with primary Sjogren's syndrome. JAutoimmun 2014, 51:89-98.
14. Matsushita T., Hasegawa M., Yanaba K., Kodera M., Takehara K., Sato S. Elevated serum BAFF levels in patients with systemic sclerosis: enhanced BAFF signaling in systemic sclerosis B lymphocytes. Arthritis Rheum 2006, 54:192-201.
15. Xue J., Kass D.J., Bon J., Vuga L., Tan J., Csizmadia E., et al. Plasma B lymphocyte stimulator and B cell differentiation in idiopathic pulmonary fibrosis patients. JImmunol Balt Md 2013, 191:2089-2095.
16. Gasse P., Mary C., Guenon I., Noulin N., Charron S., Schnyder-Candrian S., et al. IL-1R1/MyD88 signaling and the inflammasome are essential in pulmonary inflammation and fibrosis in mice. JClin Invest 2007, 117:3786-3799.
17. Gasse P., Riteau N., Charron S., Girre S., Fick L., Pétrilli V., et al. Uric acid is a danger signal activating NALP3 inflammasome in lung injury inflammation and fibrosis. Am J Respir Crit Care Med 2009, 179:903-913.
18. Riteau N., Gasse P., Fauconnier L., Gombault A., Couegnat M., Fick L., et al. Extracellular ATP is a danger signal activating P2X7 receptor in lung inflammation and fibrosis. Am J Respir Crit Care Med 2010, 182:774-783.
19. Gasse P., Riteau N., Vacher R., Michel M.-L., Fautrel A., di Padova F., et al. IL-1 and IL-23 mediate early IL-17A production in pulmonary inflammation leading to late fibrosis. Plos One 2011, 6:e23185.
20. Mi S., Li Z., Yang H.-Z., Liu H., Wang J.-P., Ma Y.-G., et al. Blocking IL-17A promotes the resolution of pulmonary inflammation and fibrosis via TGF-beta1-dependent and -independent mechanisms. JImmunol Balt Md 2011, 187:3003-3014.
21. Sonnenberg G.F., Nair M.G., Kirn T.J., Zaph C., Fouser L.A., Artis D. Pathological versus protective functions of IL-22 in airway inflammation are regulated by IL-17A. JExp Med 2010, 207:1293-1305.
22. Mackay F., Schneider P. Cracking the BAFF code. Nat Rev Immunol 2009, 9:491-502.
23. Scapini P., Carletto A., Nardelli B., Calzetti F., Roschke V., Merigo F., et al. Proinflammatory mediators elicit secretion of the intracellular B-lymphocyte stimulator pool (BLyS) that is stored in activated neutrophils: implications for inflammatory diseases. Blood 2005, 105:830-837.
24. Mackay F., Schneider P., Rennert P., Browning J. BAFF AND APRIL: a tutorial on B cell survival. Annu Rev Immunol 2003, 21:231-264.
25. Mackay F., Leung H. The role of the BAFF/APRIL system on T cell function. Semin Immunol 2006, 18:284-289.
26. Chu V.T., Enghard P., Riemekasten G., Berek C. Invitro and invivo activation induces BAFF and APRIL expression in B cells. JImmunol Balt Md 1950, 2007(179):5947-5957.
27. Alsaleh G., Messer L., Semaan N., Boulanger N., Gottenberg J.-E., Sibilia J., et al. BAFF synthesis by rheumatoid synoviocytes is positively controlled by alpha5beta1 integrin stimulation and is negatively regulated by tumor necrosis factor alpha and Toll-like receptor ligands. Arthritis Rheum 2007, 56:3202-3214.
28. Gottenberg J.-E., Cagnard N., Lucchesi C., Letourneur F., Mistou S., Lazure T., et al. Activation of IFN pathways and plasmacytoid dendritic cell recruitment in target organs of primary Sjögren's syndrome. Proc Natl Acad Sci USA 2006, 103:2770-2775.
29. Ittah M., Miceli-Richard C., Gottenberg J.-E., Sellam J., Lepajolec C., Mariette X. B-cell-activating factor expressions in salivary epithelial cells after dsRNA virus infection depends on RNA-activated protein kinase activation. Eur J Immunol 2009, 39:1271-1279.
30. Fletcher C.A., Groom J.R., Woehl B., Leung H., Mackay C., Mackay F. Development of autoimmune nephritis in genetically asplenic and splenectomized BAFF transgenic mice. JAutoimmun 2011, 36:125-134.
31. Mackay F., Sierro F., Grey S.T., Gordon T.P. The BAFF/APRIL system: an important player in systemic rheumatic diseases. Curr Dir Autoimmun 2005, 8:243-265.
32. Mackay F., Woodcock S.A., Lawton P., Ambrose C., Baetscher M., Schneider P., et al. Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. JExp Med 1999, 190:1697-1710.
33. Schiemann B., Gommerman J.L., Vora K., Cachero T.G., Shulga-Morskaya S., Dobles M., et al. An essential role for BAFF in the normal development of B cells through a BCMA-independent pathway. Science 2001, 293:2111-2114.
34. Glaccum M.B., Stocking K.L., Charrier K., Smith J.L., Willis C.R., Maliszewski C., et al. Phenotypic and functional characterization of mice that lack the type I receptor for IL-1. JImmunol Balt Md 1950, 1997(159):3364-3371.
35. Ye P., Rodriguez F.H., Kanaly S., Stocking K.L., Schurr J., Schwarzenberger P., et al. Requirement of interleukin 17 receptor signaling for lung CXC chemokine and granulocyte colony-stimulating factor expression, neutrophil recruitment, and host defense. JExp Med 2001, 194:519-527.
36. Meijerink J., Mandigers C., van de Locht L., Tönnissen E., Goodsaid F., Raemaekers J. Anovel method to compensate for different amplification efficiencies between patient DNA samples in quantitative real-time PCR. JMol Diagn 2001, 3:55-61.
37. Crestani B., Dehoux M., Hayem G., Leçon V., Hochedez F., Marchal J., et al. Differential role of neutrophils and alveolar macrophages in hepatocyte growth factor production in pulmonary fibrosis. Lab Investig J Tech Methods Pathol 2002, 82:1015-1022.
38. Wilson M.S., Madala S.K., Ramalingam T.R., Gochuico B.R., Rosas I.O., Cheever A.W., et al. Bleomycin and IL-1beta-mediated pulmonary fibrosis is IL-17A dependent. JExp Med 2010, 207:535-552.
39. Scapini P., Nardelli B., Nadali G., Calzetti F., Pizzolo G., Montecucco C., et al. G-CSF-stimulated neutrophils are a prominent source of functional BLyS. JExp Med 2003, 197:297-302.
40. Holden N.J., Williams J.M., Morgan M.D., Challa A., Gordon J., Pepper R.J., et al. ANCA-stimulated neutrophils release BLyS and promote B cell survival: a clinically relevant cellular process. Ann Rheum Dis 2011, 70:2229-2233.
41. Jablonska E., Slodczyk B., Wawrusiewicz-Kurylonek N., Garley M., Dziemianczyk D., Kretowski A., et al. Overexpression of B cell-activating factor (BAFF) in neutrophils of oral cavity cancer patients - preliminary study. Neoplasma 2011, 58:211-216.
42. Krumbholz M., Specks U., Wick M., Kalled S.L., Jenne D., Meinl E. BAFF is elevated in serum of patients with Wegener's granulomatosis. JAutoimmun 2005, 25:298-302.
43. Palanichamy A., Bauer J.W., Yalavarthi S., Meednu N., Barnard J., Owen T., et al. Neutrophil-mediated IFN activation in the bone marrow alters B cell development in human and murine systemic lupus erythematosus. JImmunol Balt Md 2014, 192:906-918.
44. Sawicka-Powierza J., Jablonska E., Kloczko J., Piszcz J., Garley M., Ratajczk-Wrona W. Evaluation of TNF superfamily molecules release by neutrophils and B leukemic cells of patients with chronic B - cell lymphocytic leukemia. Neoplasma 2011, 58:45-50.
45. Bossen C., Cachero T.G., Tardivel A., Ingold K., Willen L., Dobles M., et al. TACI, unlike BAFF-R, is solely activated by oligomeric BAFF and APRIL to supportsurvival of activated B cells and plasmablasts. Blood 2008, 111:1004-1012.
46. Dagur P.K., Biancotto A., Wei L., Sen H.N., Yao M., Strober W., et al. MCAM-expressing CD4(+) T cells in peripheral blood secrete IL-17A and are significantly elevated in inflammatory autoimmune diseases. JAutoimmun 2011, 37:319-327.
47. François A., Chatelus E., Wachsmann D., Sibilia J., Bahram S., Alsaleh G., et al. Blymphocytes and B-cell activating factor promote collagen and profibrotic markers expression by dermal fibroblasts in systemic sclerosis. Arthritis Res Ther 2013, 15:R168.
48. Yoshimoto K., Tanaka M., Kojima M., Setoyama Y., Kameda H., Suzuki K., et al. Regulatory mechanisms for the production of BAFF and IL-6 are impaired in monocytes of patients of primary Sjögren's syndrome. Arthritis Res Ther 2011, 13:R170.
49. Doreau A., Belot A., Bastid J., Riche B., Trescol-Biemont M.-C., Ranchin B., et al. Interleukin 17 acts in synergy with B cell-activating factor to influence B cell biology and the pathophysiology of systemic lupus erythematosus. Nat Immunol 2009, 10:778-785.
50. Lai Kwan Lam Q., King Hung Ko O., Zheng B.-J., Lu L. Local BAFF gene silencing suppresses Th17-cell generation and ameliorates autoimmune arthritis. Proc Natl Acad Sci USA 2008, 105:14,993-14,998.
51. Zhou X., Xia Z., Lan Q., Wang J., Su W., Han Y.-P., et al. BAFF promotes Th17 cells and aggravates experimental autoimmune encephalomyelitis. Plos One 2011, 6:e23629.
52. Novobrantseva T.I., Majeau G.R., Amatucci A., Kogan S., Brenner I., Casola S., et al. Attenuated liver fibrosis in the absence of B cells. JClin Invest 2005, 115:3072-3082.
53. Komura K., Yanaba K., Horikawa M., Ogawa F., Fujimoto M., Tedder T.F., et al. CD19 regulates the development of bleomycin-induced pulmonary fibrosis in a mouse model. Arthritis Rheum 2008, 58:3574-3584.